Browse psychedelic research by topic
Browse 49 topics by Regulators and organisations, Countries, compounds and conditions, Kinds of news, with the latest top picks and key developments.
Regulators and organisations
Follow one regulator, sponsor or research organisation
- TGA (Australia)TGA publishes interim scheduling decisions on Poisons Standard amendments from ACMS #47 and Joint ACMS-ACCS #40No new picks in the past 30 days
- FDA (United States)Compass Pathways submits COMP360 psilocybin new drug application to FDA for treatment-resistant depression1 in the past 30 days
- DEA (United States)US Drug Enforcement Administration scheduling actions, production quotas, registrations and enforcement.No new picks in the past 30 days
- EMA (European Union)European Medicines Agency opinions, guidance and workshops relevant to psychedelic medicines.No new picks in the past 30 days
- MHRA (United Kingdom)UK medicines regulator decisions, licences and guidance.No new picks in the past 30 days
- Health CanadaSpecial Access Program decisions, exemptions and notices from Health Canada.No new picks in the past 30 days
- World Health OrganizationWHO reviews and recommendations, including the Expert Committee on Drug Dependence.No new picks in the past 30 days
- Compass PathwaysCompass Pathways submits COMP360 psilocybin new drug application to FDA for treatment-resistant depression1 in the past 30 days
- MindMedTrial milestones, results and regulatory steps for MM120 and other programs.No new picks in the past 30 days
- CybinTrial milestones, results and regulatory steps for CYB003 and CYB004.No new picks in the past 30 days
- AtaiBeckleyPrograms from atai Life Sciences and Beckley Psytech, including BPL-003.No new picks in the past 30 days
- Lykos TherapeuticsMDMA-assisted therapy program news, regulatory steps and company changes.No new picks in the past 30 days
- MAPSResearch, policy and education news from the Multidisciplinary Association for Psychedelic Studies.No new picks in the past 30 days
- Usona InstituteNon-profit psilocybin and 5-MeO-DMT research programs.No new picks in the past 30 days
Countries, compounds and conditions
Follow one jurisdiction, compound or condition
- AustraliaTGA publishes interim scheduling decisions on Poisons Standard amendments from ACMS #47 and Joint ACMS-ACCS #40No new picks in the past 30 days
- United StatesCompass Pathways submits COMP360 psilocybin new drug application to FDA for treatment-resistant depression2 in the past 30 days
- European UnionEU and member-state regulation, trials and funding.No new picks in the past 30 days
- United KingdomUK advisory council publishes updated review of ketamine use and harmsNo new picks in the past 30 days
- CanadaFederal and provincial law, access programs and trials in Canada.No new picks in the past 30 days
- New ZealandLaw, regulation and trials in New Zealand.No new picks in the past 30 days
- InternationalWHO, United Nations and multi-country matters.No new picks in the past 30 days
- PsilocybinCompass Pathways submits COMP360 psilocybin new drug application to FDA for treatment-resistant depression2 in the past 30 days
- MDMATGA publishes interim scheduling decisions on Poisons Standard amendments from ACMS #47 and Joint ACMS-ACCS #40No new picks in the past 30 days
- LSDDefinium says LSD therapy DT120 eased anxiety in second late-stage trialNo new picks in the past 30 days
- DMT and ayahuascaTrials and papers about DMT and ayahuasca.No new picks in the past 30 days
- 5-MeO-DMTTrials and papers about 5-MeO-DMT.No new picks in the past 30 days
- IbogaineFDA seeks public input on early-phase ibogaine trial designNo new picks in the past 30 days
- Ketamine and esketamineUK advisory council publishes updated review of ketamine use and harmsNo new picks in the past 30 days
- Novel compoundsNew and modified compounds, including non-hallucinogenic analogues.No new picks in the past 30 days
- DepressionCompass Pathways submits COMP360 psilocybin new drug application to FDA for treatment-resistant depression2 in the past 30 days
- PTSDFDA seeks public input on early-phase ibogaine trial designNo new picks in the past 30 days
- AnxietyNYU Langone registers trial of psilocybin-assisted psychotherapy for fear of cancer recurrence in early-stage breast cancer1 in the past 30 days
- AddictionFDA seeks public input on early-phase ibogaine trial designNo new picks in the past 30 days
- End-of-life distressDistress in life-threatening illness and palliative care.No new picks in the past 30 days
- MechanismsSystematic review examines the effect of psychedelics on associative learningNo new picks in the past 30 days
- Therapy modelsSystematic review examines the effect of psychedelics on associative learningNo new picks in the past 30 days
- Harm reductionEvidence and services that reduce harm outside clinical settings.No new picks in the past 30 days
Kinds of news
Browse by kind: law changes, regulator decisions, trial results, papers, safety
- Law changesBills, acts, regulations and drug scheduling introduced, passed or in force.No new picks in the past 30 days
- Regulator decisionsTGA publishes final Poisons Standard decisions from ACCS #40 and Joint ACMS-ACCS #39No new picks in the past 30 days
- Guidance and consultationsFDA seeks public input on early-phase ibogaine trial designNo new picks in the past 30 days
- Access and fundingPrescriber and access schemes, reimbursement and public research funding.No new picks in the past 30 days
- Courts and enforcementRulings, exemptions and enforcement actions.No new picks in the past 30 days
- Trial registrationsCompass Pathways submits COMP360 psilocybin new drug application to FDA for treatment-resistant depression2 in the past 30 days
- Trial resultsDefinium says LSD therapy DT120 eased anxiety in second late-stage trialNo new picks in the past 30 days
- PapersPeer-reviewed papers and preprints.No new picks in the past 30 days
- ReviewsSystematic review examines the effect of psychedelics on associative learningNo new picks in the past 30 days
- SafetyAdverse events, risk findings and safety alerts.No new picks in the past 30 days
- Practice and trainingClinical guidelines, protocols and training standards.No new picks in the past 30 days
- Analysis and opinionCommentary, forecasts and interviews.No new picks in the past 30 days